Skip to main content
Research
  1. Queen Mary University of London
  2. Research
  3. Publications

Publications: Dr Hamish Miller

Back to Search
Miller H, Brandhof EVD, Simpson J, Denham S, Harman D, Aithal GP, Manousou P, Cobbold J et al. ( 2025 ) . FP13 The urine steroid metabolome combined with machine learning performs similarly to established non-invasive markers to identify advanced MASLD fibrosis . Conference: Flash Presentationsa64.1 - a6a64 .
Miller H, van den Brandhof E, Simpson J, Denham S, Harman D, Aithal G, Manousou P, Cobbold J et al. ( 2025 ) . WED-419 The urine steroid metabolome combined with machine learning performs similarly to established non-invasive markers to risk stratify for the presence of advanced MASLD fibrosis . Journal of Hepatology vol. 82 , s550 - s551 .
Spiers J, Li W, Aravinthan AD, Bannaga A, Caddick K, Culver EL, Faulkes RE, Gordon V et al. ( 2025 ) . Current Surveillance Strategy Is Less Effective for Detecting Early-Stage Hepatocellular Carcinoma in Patients with Non-Viral and Non-Cirrhotic Liver Disease . Liver Cancer vol. 14 , ( 5 ) 587 - 600 .
Colosimo S, Miller H, Koutoukidis DA, Marjot T, Tan GD, Harman DJ, Aithal GP, Manousou P et al. ( 2024 ) . Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD . Diabetes Research and Clinical Practice vol. 217 ,
Miller H, Garrido P, Li W, Kumar R, Gines I, Nikolaou N, Potter T, Neville M et al. ( 2024 ) . THU-236-YI Oxysterol treatment causes indirect stellate cell activation: a potential mechanism linking steroid metabolising enzyme dysregulation with fibrosis . Journal of Hepatology vol. 80 ,
Miller H, Harman D, Aithal GP, Manousou P, Cobbold JF, Parker R, Sheridan D, Newsome PN et al. ( 2024 ) . Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study . BMJ Open vol. 14 , ( 1 )
Colosimo S, Miller H, Koutoukidis D, Marjot T, Harman D, Aithal G, Manousou P, Forlano R et al. ( 2023 ) . The role of glycated haemoglobin in predicting disease severity in non-alcoholic fatty liver disease . Endocrine Abstracts
Li W, Sheridan D, McPherson S, Alazawi W, Abeysekera K, Marjot T, Brennan P, Mahgoub S et al. ( 2023 ) . National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022 . JHEP Reports vol. 5 , ( 12 )
Mir IG, Kumar R, Garrido P, Li W, Miller H, Saihi H, Hood G, Alazawi W ( 2023 ) . FRI-520 B-cell activating factor in non-alcoholic steatohepatitis . Journal of Hepatology vol. 78 ,
Miller H, Colosimo S, Li W, Cobbold J, Alazawi W, Harman D, Aithal G, Manousou P et al. ( 2023 ) . SAT-483 Developing a risk stratification tool for advanced NAFLD fibrosis using routinely measured clinical variables in a diabetes clinic annual review . Journal of Hepatology vol. 78 ,
Atabaki NN, Coral DE, Pomares-Millan H, Smith K, Behjat HH, Koivula RW, Tura A, Miller H et al. . A Biological-Systems-Based Analyses Using Proteomic and Metabolic Network Inference Reveals Mechanistic Insights into Hepatic Lipid Accumulation: An IMI-DIRECT Study .
Back to Search